Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q1 FY22 results · Apr–Jun 2021
Alkem Laboratories reported revenue from operations of ₹2,731.36 crore (up 36.3% from Q1 FY21) and net profit of ₹480.23 crore (up 13.5% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,731.36 | 2,003.49 | +36.3% | 2,192.16 | +24.6% |
| Other income | 46.65 | 43.50 | +7.2% | 46.28 | +0.8% |
| Total income | 2,778.01 | 2,046.99 | +35.7% | 2,238.44 | +24.1% |
| Profit before tax | 556.12 | 492.75 | +12.9% | 258.16 | +115.4% |
| Net profit for the period | 480.23 | 423.19 | +13.5% | 249.22 | +92.7% |
| Attributable to shareholders of the company | 468.12 | 422.01 | +10.9% | 239.99 | +95.1% |
| EPS, basic (₹) | 39.15 | 35.30 | +10.9% | 20.07 | +95.1% |
| Net margin (%) | 17.6 | 21.1 | 11.4 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,278.67 | 1,550.85 | +46.9% | 1,917.47 | +18.8% |
| Other income | 39.21 | 32.45 | +20.8% | 48.77 | −19.6% |
| Total income | 2,317.88 | 1,583.30 | +46.4% | 1,966.24 | +17.9% |
| Profit before tax | 529.00 | 479.13 | +10.4% | 395.66 | +33.7% |
| Net profit for the period | 469.27 | 426.16 | +10.1% | 362.74 | +29.4% |
| EPS, basic (₹) | 39.25 | 35.64 | +10.1% | 30.34 | +29.4% |
| Net margin (%) | 20.6 | 27.5 | 18.9 |
Consolidated
- Filed with BSE
- 06 Aug 2021, 18:01 IST
- Board meeting
- 06 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2021, 18:01 IST
- Board meeting
- 06 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE